Improvement of cardiac function after implanting the osteopontin-derived peptide SVVYGLR in a hamster model of dilated cardiomyopathy.

Abstract

OBJECTIVES:

Osteopontin is a multifunctional cytokine that can modulate a variety of cellular activities, such as fibrotic response and inflammation. Osteopontin-derived peptide Ser-Val-Val-Tyr-Gly-Leu-Arg (SVVYGLR; SV) induces angiogenesis and the expression of smooth muscle actin (SMA) in fibroblasts. In this study, we determined the effects of SV peptide on dilated cardiomyopathy (DCM).

METHODS:

Gels containing SV peptide (SV group), a random SV peptide (GYRVLSV) (random group) or a simple phosphate-buffered saline solution (PBS group) were transplanted on to the left ventricular (LV) anterior wall of a DCM hamster model. A control group simply underwent chest opening and closing. We used echocardiography to measure cardiac function before gel implantation (week 0) and 2, 4, 6 and 8 weeks after gel implantation. Changes in histology and myocardial remodelling were evaluated 8 weeks after the gel implantation.

RESULTS:

At 8 weeks post-treatment, the SV group had significantly better maintained cardiac function compared with the other groups. Histological analysis showed that LV chamber dilatation and cardiomyocyte hypertrophy were significantly attenuated, and the distribution of SMA-positive cells in the LV anterior wall area was greater in the SV group. The capillary density in the epicardial aspect of the anterior wall in the SV group was also significantly increased, indicating that the SV peptide released from the implanted gel had promoted angiogenesis. Furthermore, Western blotting and histological analyses showed that the level of expression of collagen type III at the gel-implanted anterior wall in the SV group was significantly increased, and the type III/type I collagen ratio was higher in the SV group than in the control or PBS groups.

CONCLUSIONS:

SV peptide treatment improved cardiac function, and inhibited the dilatation of the LV chamber and cardiomyocyte hypertrophy. By inducing the differentiation of fibroblasts to SMA-positive muscle-like cells and increasing type III collagen, SV peptide conferred a contractile property on the gel-implanted wall. We believe that the SVVYGLR peptide treatment could be used as a bridge to a left ventricular assist device and heart transplantation and for cardiac regeneration therapy without cell transplantation in the future.

• Authors: Yoko Mizuno, Ayako Uchinaka, Yoshihito Horii, Seiji Mori, Yoshinosuke Hamada, Shigeru Miyagawa, Atsuhiro Saito, Yoshiki Sawa, Nariaki Matsuura, Naomasa Kawaguchi
• Journal: Interactive cardiovascular and thoracic surgery (Interact Cardiovasc Thorac Surg) Vol. 21 Issue 4 Pg. 506-14 (Oct 2015) ISSN: 1569-9285 [Electronic] England
• PMID: 26188018 (Publication Type: Journal Article)
• Copyright: © The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Chemical References

• Angiogenesis Inducing Agents
• Gels
• Oligopeptides
• SVVYGLR peptide
• Osteopontin

Topics

• Administration, Topical
• Angiogenesis Inducing Agents (administration & dosage)
• Animals
• Cardiomyopathy, Dilated (drug therapy, physiopathology)
• Cricetinae
• Disease Models, Animal
• Gels (administration & dosage)
• Heart Ventricles (drug effects)
• Male
• Myocardium (metabolism)
• Oligopeptides (administration & dosage)
• Osteopontin (metabolism)
• Treatment Outcome